We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Albemarle Corporation (ALB - Free Report) announced that it is introducing a new technology for the Fluid Catalytic Cracking ("FCC") catalyst market dubbed Granite.
The new technology platform is based on novel matrix/binder system, which expands the catalyst formulation window. This enables refiners maximize profitability through better bottoms upgrading, higher zeolite stability and improved coke selectivity while achieving targeted product yields. Albemarle stated that the first catalyst product lines under the Granite technology platform are Everest, Peak and Denali.
The new technology strengthens the company's long-standing leadership and expands FCC product portfolio. It also offers new options for customers to focus on petrochemical or fuel production. The technology also provides improved performance and operational flexibility to customers.
Shares of Albemarle have declined 2.1% in the past three months, against the industry’s 5.5% growth.
In November, Albemarle raised guidance for 2017 and it now expects full-year net sales of between $3 billion and $3.05 billion (compared with the prior view of $2.90-$3.05 billion), adjusted earnings per share between $4.40 and $4.50 (compared with the prior view of $4.20 and $4.40) and adjusted EBITDA of $860-$875 million (compared with $835-$875 million expected earlier).
Albemarle remains focused on strengthening its lithium business. The company is well placed to leverage strong expected growth in the battery-grade lithium market. Albemarle is executing a number of projects that are likely to boost its global lithium derivative capacity to 165,000 metric tons by 2021.
Additionally, the company’s strategy to sell non-core businesses and assets is likely to boost growth opportunities and focus on its key businesses.
Westlake Chemical has an expected long-term earnings growth rate of 10.6%. Its shares have risen 83.8% year to date.
Daqo New Energy has an expected long-term earnings growth rate of 7%. Its shares have surged a whopping 151.3% year to date.
Kronos Worldwide has an expected long-term earnings growth rate of 5%. Its shares have rallied 115.1% year to date.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Image: Bigstock
Albemarle Launches Granite Technology, Boosts FCC Portfolio
Albemarle Corporation (ALB - Free Report) announced that it is introducing a new technology for the Fluid Catalytic Cracking ("FCC") catalyst market dubbed Granite.
The new technology platform is based on novel matrix/binder system, which expands the catalyst formulation window. This enables refiners maximize profitability through better bottoms upgrading, higher zeolite stability and improved coke selectivity while achieving targeted product yields. Albemarle stated that the first catalyst product lines under the Granite technology platform are Everest, Peak and Denali.
The new technology strengthens the company's long-standing leadership and expands FCC product portfolio. It also offers new options for customers to focus on petrochemical or fuel production. The technology also provides improved performance and operational flexibility to customers.
Shares of Albemarle have declined 2.1% in the past three months, against the industry’s 5.5% growth.
In November, Albemarle raised guidance for 2017 and it now expects full-year net sales of between $3 billion and $3.05 billion (compared with the prior view of $2.90-$3.05 billion), adjusted earnings per share between $4.40 and $4.50 (compared with the prior view of $4.20 and $4.40) and adjusted EBITDA of $860-$875 million (compared with $835-$875 million expected earlier).
Albemarle remains focused on strengthening its lithium business. The company is well placed to leverage strong expected growth in the battery-grade lithium market. Albemarle is executing a number of projects that are likely to boost its global lithium derivative capacity to 165,000 metric tons by 2021.
Additionally, the company’s strategy to sell non-core businesses and assets is likely to boost growth opportunities and focus on its key businesses.
Albemarle Corporation Price and Consensus
Albemarle Corporation Price and Consensus | Albemarle Corporation Quote
Zacks Rank & Key Picks
Albemarle currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the basic materials space are Westlake Chemical Corporation (WLK - Free Report) , Daqo New Energy Corp. (DQ - Free Report) and Kronos Worldwide Inc. (KRO - Free Report) , each sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Westlake Chemical has an expected long-term earnings growth rate of 10.6%. Its shares have risen 83.8% year to date.
Daqo New Energy has an expected long-term earnings growth rate of 7%. Its shares have surged a whopping 151.3% year to date.
Kronos Worldwide has an expected long-term earnings growth rate of 5%. Its shares have rallied 115.1% year to date.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>